Hepatocutaneous Syndrome in Dogs: Skin Lesions Linked to Liver Disease

Based on peer reviewed veterinary research · For educational purposes only · Updated October 2026 · 10 min read

Photo by Alexander Mass on Unsplash

Hepatocutaneous syndrome, also known as superficial necrolytic dermatitis or necrolytic migratory erythema, is among the most serious skin conditions veterinarians encounter in older dogs. Unlike most dermatological diseases that originate within the skin itself, hepatocutaneous syndrome is a systemic metabolic disorder in which severe liver dysfunction causes devastating changes to the skin, particularly the footpads. The connection between the liver and the skin may seem surprising, but the liver plays an essential role in protein metabolism, and when it fails to process amino acids properly, the skin is one of the first tissues to suffer.

This condition is rare, with an estimated prevalence of less than one percent of all canine dermatological cases, but its clinical presentation is striking and its impact on the affected dog is profound. The dramatic paw pad crusting, facial erosions, and rapid clinical decline often leave owners feeling overwhelmed. Early recognition and aggressive nutritional support can improve comfort and extend quality survival time, even though the underlying liver disease carries a guarded long-term prognosis.

This article provides a comprehensive overview of hepatocutaneous syndrome, from the metabolic mechanisms that connect liver disease to skin damage, through the clinical presentation, diagnostic approach, and the supportive treatments that can make a meaningful difference in the lives of affected dogs.

Understanding the Liver-Skin Connection

The liver is the body's metabolic powerhouse, responsible for processing amino acids absorbed from dietary protein, synthesizing albumin and other essential proteins, storing glycogen, detoxifying metabolic waste products, and producing bile for fat digestion. When the liver becomes severely compromised, its ability to process and redistribute amino acids to other tissues breaks down.

Amino Acid Depletion

In hepatocutaneous syndrome, the failing liver appears to consume or catabolize amino acids at an accelerated rate while simultaneously losing the ability to release them into the bloodstream at adequate concentrations. The result is a severe plasma hypoaminoacidemia, a deficiency of circulating amino acids that starves rapidly dividing tissues of their essential protein building blocks. The skin, which requires a constant supply of amino acids to maintain the epidermal barrier and produce keratin, is particularly vulnerable.

The keratinocytes in the epidermis depend on amino acids to produce keratin proteins, maintain cell-to-cell connections, and undergo their normal cycle of division, maturation, and shedding. When amino acid supply is critically low, the epidermis essentially falls apart. Cells die prematurely (necrolysis), lose their cohesion, and the surface layers crack and ulcerate. This is especially evident on the paw pads, where the epidermis is thick and has high metabolic demands.

Causes and Risk Factors

Hepatic Vacuolar Hepatopathy

The most common liver pathology associated with hepatocutaneous syndrome is a distinctive vacuolar hepatopathy in which hepatocytes (liver cells) develop massive glycogen or lipid vacuolation, creating the characteristic honeycomb appearance on ultrasound. This hepatopathy may be idiopathic (of unknown cause) or may develop secondary to chronic exposure to anticonvulsant medications, particularly phenobarbital and primidone.

Glucagon-Secreting Tumors

In a smaller percentage of cases, hepatocutaneous syndrome is caused by a glucagonoma, a tumor of the pancreatic alpha cells that secretes excessive amounts of glucagon. Glucagon promotes amino acid catabolism in the liver, leading to the same pattern of hypoaminoacidemia and skin damage seen with primary liver disease. This variant is more commonly described in humans (where the condition is called necrolytic migratory erythema) but has been documented in dogs.

Patient Demographics

Hepatocutaneous syndrome most commonly affects older dogs, with the median age at diagnosis being approximately 10 years. Males and females are affected with roughly equal frequency. No strong breed predisposition has been consistently demonstrated, though the condition has been reported in a wide range of breeds including West Highland White Terriers, Scottish Terriers, Shetland Sheepdogs, Cocker Spaniels, and German Shepherd Dogs.

Severe paw pad crusting and fissuring is the hallmark clinical sign of hepatocutaneous syndrome in dogs.

Photo by Tima Miroshnichenko on Pexels

Clinical Signs and Presentation

Paw Pad Lesions

The single most recognizable feature of hepatocutaneous syndrome is the severe, symmetrical involvement of all four paw pads. The pads become markedly thickened, cracked, fissured, and covered with adherent, horn-like crusts. The fissures can be deep enough to reach the dermis, causing significant pain and lameness. Affected dogs may be reluctant to walk, may shift their weight constantly, and may lick their feet obsessively. Some dogs develop secondary bacterial or fungal infections in the fissured paw pads, compounding the discomfort.

Facial and Mucocutaneous Lesions

Erosions, crusting, and erythema frequently develop on the muzzle, periocular region (around the eyes), ear margins, and mucocutaneous junctions (where skin meets mucous membrane) such as the lips, nostrils, and perianal area. The pressure points of the elbows and hocks are also commonly affected. These lesions are typically erythematous, well-demarcated, and covered with crusts that, when removed, reveal moist, oozing erosions beneath.

Systemic Signs

Because hepatocutaneous syndrome reflects severe underlying liver disease, affected dogs often show systemic signs beyond the skin. Weight loss, lethargy, decreased appetite, increased thirst and urination, and sometimes vomiting or diarrhea may precede or accompany the skin lesions. Some owners report that the systemic signs appeared first, with skin lesions developing weeks to months later.

The rapid and dramatic nature of the skin changes, particularly the paw pad lesions, often prompts urgent veterinary evaluation. Unlike most dermatological conditions that develop gradually, hepatocutaneous syndrome can progress from normal-appearing paw pads to severe crusting and fissuring within just a few weeks.

Diagnostic Workup

Skin Biopsy

Skin biopsy is one of the first and most important diagnostic steps. Histopathology reveals a highly characteristic pattern called the red, white, and blue pattern: parakeratotic hyperkeratosis (blue) at the surface, a zone of pale, edematous, degenerating keratinocytes in the upper epidermis (white), and hyperplasia of the basal cell layer (red). This tricolor pattern on H&E staining is virtually pathognomonic for superficial necrolytic dermatitis and immediately distinguishes it from other causes of paw pad disease.

Abdominal Ultrasound

Abdominal ultrasound is essential and typically reveals the diagnostic honeycomb or Swiss cheese liver pattern, characterized by widespread hypoechoic (dark) nodules interspersed with hyperechoic (bright) areas throughout the liver parenchyma. This pattern represents the severe vacuolar hepatopathy and is so distinctive that many radiologists and internists consider it nearly pathognomonic for hepatocutaneous syndrome when combined with compatible skin lesions.

Bloodwork

Blood chemistry typically reveals markedly elevated liver enzymes (ALP, ALT, GGT), low albumin (hypoalbuminemia), low blood glucose (hypoglycemia), and elevated bile acids. Amino acid profiling, when available, shows globally depressed plasma amino acid levels. A complete blood count may reveal mild anemia and stress leukogram changes.

Imaging studies to evaluate the pancreas are warranted if no liver pathology is identified, as a glucagonoma should be considered in the differential. CT or specialized ultrasound examination of the pancreas can help identify tumors too small to detect on routine abdominal ultrasound.

Treatment and Supportive Care

Intravenous Amino Acid Infusions

The cornerstone of treatment for hepatocutaneous syndrome is replenishing depleted amino acid stores through intravenous amino acid infusions. A standard protocol involves administering a commercially available crystalline amino acid solution (typically 3 to 5 percent amino acid solution) as a constant-rate infusion over 6 to 8 hours, repeated every 7 to 14 days initially. Many dogs show visible improvement in skin lesions within one to two weeks of starting infusions, with paw pad crusting softening and fissures beginning to heal.

Dietary Management

A high-protein, high-quality diet supports amino acid availability between infusions. Diets rich in easily digestible protein from sources like eggs, cottage cheese, lean meats, and commercial hepatic support diets are typically recommended. Some veterinarians supplement with specific amino acids such as zinc, which is often depleted in liver disease and plays a critical role in skin integrity. Egg yolks are particularly valuable because they provide a complete amino acid profile in a highly digestible form.

Paw Pad Care

Gentle, consistent paw pad care significantly improves comfort. Soaking the feet in warm water helps soften thick crusts, which can then be gently debrided. Applying a veterinary-approved emollient or petroleum-based product to the pads after soaking helps seal moisture into the tissue and reduces fissuring. Protective booties can shield painful pads during walks, and soft indoor surfaces reduce impact on compromised footpads.

Managing Secondary Infections

The cracked, ulcerated skin of hepatocutaneous syndrome is highly susceptible to secondary bacterial and yeast infections. Topical antimicrobial sprays containing chlorhexidine help maintain surface hygiene, while systemic antibiotics may be necessary for established infections. Yeast overgrowth, particularly Malassezia, is common on the moist, damaged skin and may require concurrent antifungal therapy.

Pain Management

Because paw pad lesions can cause significant pain and lameness, appropriate pain management is an important component of care. Your veterinarian may prescribe analgesics, anti-inflammatory medications, or gabapentin, depending on the severity of discomfort and the patient's overall liver function, which affects medication metabolism.

Prognosis and Quality of Life

Hepatocutaneous syndrome carries a guarded to poor long-term prognosis because the underlying liver disease is typically progressive and irreversible. Median survival times reported in veterinary literature range from approximately three to six months after diagnosis, though individual variation is substantial. Some dogs maintained on aggressive amino acid infusion protocols and dietary support survive well beyond a year with acceptable quality of life.

The quality of life between amino acid infusions is often the key factor in management decisions. Dogs that respond well to infusions may experience two to three weeks of improved comfort, with paw pads softening, appetite improving, and energy increasing. As the infusion effect wanes, symptoms may gradually return, signaling the need for the next treatment cycle.

For dogs with glucagonoma-associated hepatocutaneous syndrome, surgical removal of the pancreatic tumor, when feasible, can lead to dramatic and sometimes sustained improvement if the liver has not been irreversibly damaged. However, glucagonomas are often advanced at the time of diagnosis, and surgical candidacy depends on tumor location, metastatic status, and the patient's overall condition.

Open, ongoing conversations with your veterinarian about quality of life, treatment burden, and realistic expectations are essential for navigating this challenging diagnosis. Monitoring tools such as quality-of-life scoring scales can help objectify the assessment and guide decisions about continuing or transitioning care.

Hepatocutaneous Syndrome in Dogs FAQ

Q: What is the life expectancy for a dog with hepatocutaneous syndrome?

The median survival time after diagnosis is approximately three to six months, but this varies widely. Dogs that respond well to intravenous amino acid infusions and receive aggressive nutritional support may survive a year or longer with good quality of life between treatments. The prognosis depends on the severity of the underlying liver disease and how well the dog responds to amino acid replacement therapy.

Q: What causes the paw pads to crack in hepatocutaneous syndrome?

The paw pad changes result from a critical deficiency of amino acids in the blood. The thick epidermis of the paw pads has high metabolic demands and requires a constant supply of amino acids to maintain its keratin structure. When the diseased liver fails to process and release adequate amino acids, the paw pad epidermis degenerates, losing its structural integrity and developing the characteristic fissures and crusts.

Q: Can hepatocutaneous syndrome be cured?

In most cases, hepatocutaneous syndrome cannot be cured because the underlying liver disease is progressive. However, if the condition is caused by a glucagonoma (pancreatic tumor) that can be surgically removed, resolution of skin signs is possible. For the more common liver-associated form, treatment focuses on managing symptoms and maintaining quality of life through amino acid infusions, dietary support, and skin care.

Q: How are amino acid infusions given to dogs with hepatocutaneous syndrome?

Amino acid infusions are administered intravenously, typically as a slow constant-rate infusion over 6 to 8 hours in a veterinary hospital setting. The frequency is usually every 7 to 14 days initially, adjusted based on the dog's clinical response. Some veterinary facilities can teach owners to administer subcutaneous amino acid solutions at home between intravenous treatments, though this is less common.

Q: What should I feed a dog with hepatocutaneous syndrome?

A high-protein, highly digestible diet is recommended to maximize amino acid intake. Excellent protein sources include eggs (particularly egg yolks), cottage cheese, lean chicken or turkey, and commercial hepatic support diets. Your veterinarian may also recommend zinc supplementation. Frequent small meals throughout the day can help maintain more consistent amino acid levels between intravenous infusions.

Sources

Outerbridge CA, Marks SL, Rogers QR. Plasma amino acid concentrations in 36 dogs with histologically confirmed superficial necrolytic dermatitis. Veterinary Dermatology. 2002;13(4):177-186.

Gross TL, Song MD, Havel PJ, Ihrke PJ. Superficial necrolytic dermatitis (necrolytic migratory erythema) in dogs. Veterinary Pathology. 1993;30(1):75-81.

March PA, Hillier A, Weisbrode SE, et al. Superficial necrolytic dermatitis in 11 dogs with a history of phenobarbital administration (1995-2002). Journal of Veterinary Internal Medicine. 2004;18(1):65-74.

Cave NJ, Marks SL, Kass PH, et al. Evaluation of a routine diagnostic fecal panel for dogs with diarrhea. Journal of the American Veterinary Medical Association. 2002;221(1):52-59.

Turek MM. Cutaneous paraneoplastic syndromes in dogs and cats: a review of the literature. Veterinary Dermatology. 2003;14(6):279-296.

Related Reading

• Cushing's Disease and Skin Problems in Dogs, another systemic condition that causes secondary skin changes in dogs
• Calcinosis Cutis in Dogs, mineral deposits in the skin caused by metabolic imbalances
• Chlorhexidine for Dogs, using topical antiseptics for managing secondary skin infections
• When Dog Skin Treatment Is Not Working, investigating deeper causes when standard skin treatments fail

E. Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.